Cyclo Therapeutics, Inc. financial data

Symbol
CYTH, CYTHW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
6714 Nw 16 Th Street, Suite B, Gainesville, Florida
State of incorporation
Nevada
Fiscal year end
December 31
Former names
CTD HOLDINGS INC (to 9/30/2019), CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC (to 3/30/2000)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 104 % -52.3%
Quick Ratio 3.4 % -57.2%
Return On Equity -2.74 K % -506%
Return On Assets -253 % -2.46%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.7 M shares +172%
Common Stock, Shares, Outstanding 28.6 M shares +185%
Entity Public Float 17.2 M USD +17.2%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 28.6 M shares +160%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.6 M USD +20.5%
Costs and Expenses 21.2 M USD +12.3%
Operating Income (Loss) -20.2 M USD -14%
Nonoperating Income (Expense) 771 K USD +1655217%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -19.4 M USD -9.65%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -19.4 M USD -9.65%
Earnings Per Share, Basic -0.92 USD/shares +53.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3 M USD +227%
Accounts Receivable, after Allowance for Credit Loss, Current 71.3 K USD -45.6%
Inventory, Net 243 K USD -0.81%
Assets, Current 6.57 M USD +64.5%
Property, Plant and Equipment, Net 24.3 K USD -51.7%
Operating Lease, Right-of-Use Asset 569 K USD +967%
Assets 7.16 M USD +74.8%
Accounts Payable, Current 3.67 M USD
Liabilities, Current 6.54 M USD +45.3%
Operating Lease, Liability, Noncurrent 17.5 K USD -52.1%
Retained Earnings (Accumulated Deficit) -88.2 M USD -28.2%
Stockholders' Equity Attributable to Parent 610 K USD
Liabilities and Equity 7.16 M USD +74.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.18 M USD -41.5%
Net Cash Provided by (Used in) Financing Activities -69.3 K USD -102%
Net Cash Provided by (Used in) Investing Activities -2.42 K USD -106%
Common Stock, Shares Authorized 250 M shares +400%
Common Stock, Shares, Issued 28.6 M shares +185%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.25 M USD -895%
Interest Paid, Excluding Capitalized Interest, Operating Activities 756 USD -56.3%
Deferred Tax Assets, Valuation Allowance 24.8 M USD +7.17%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 1.03 M USD
Depreciation 19.3 K USD -1.05%
Payments to Acquire Property, Plant, and Equipment 2.42 K USD -84%
Lessee, Operating Lease, Liability, to be Paid 1.04 M USD
Property, Plant and Equipment, Gross 159 K USD +1.54%
Operating Lease, Liability, Current 648 K USD +3716%
Lessee, Operating Lease, Liability, to be Paid, Year Two 21.6 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.02 M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure -50%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.9 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.8 K USD
Deferred Tax Assets, Operating Loss Carryforwards 12.6 M USD +17.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 6.95 M USD
Additional Paid in Capital 88.8 M USD +29.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.18 K USD -54.8%
Deferred Tax Assets, Net of Valuation Allowance 230 K USD +5650%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%